Replies to post #229273 on Biotech Values

[DewDiligence]

OPGN reaches quorum for—(delayed)—3/30/20 shareholder vote on reverse-merger with CURE.AS:

https://www.globenewswire.com/news-release/2020/03/24/2005551/0/en/OpGen-Provides-Further-Update-on-Shareholder-Proxy-Voting-in-Relation-to-the-Business-Combination-with-Curetis.html

CURE.AS shareholders have already approved the merger. If OPGN’s shareholder vote on 3/30/20 proceeds without a hitch, the merger will close immediately thereafter.

[DewDiligence]

Apropos to OPGN:

https://www.prnewswire.com/news-releases/bgis-real-time-sars-cov-2-test-to-detect-novel-coronavirus-receives-fda-emergency-use-authorization-301030852.html

BGI is the supplier of COVID-19 test kits for CURE.AS (#msg-154361947), the company with whom OPGN is merging. Until now, CURE.AS was selling BGI’s kits in Europe and Asia; now they can also sell them in the US.